Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2020 Sep 14

PMID 32922011

Citations 6

Authors

Liang Kong

Shi-Meng Zhang

Jia-Hao Chu

Xin-Ze Liu

Lu Zhang

Si-Yu He

Si-Min Yang

Rui-Jun Ju

Xue-Tao Li

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) is one of the most lethal types of cancer with highly infiltrating. Chemotherapy is far from satisfactory, vasculogenic mimicry (VM) and angiogenesis results in invasion, migration and relapse.

Purpose: The objective of this study was to construct a novel CPP modified vinorelbine and dioscin liposomes by two new functional materials, DSPE-PEG-MAL and CPP-PVGLIG-PEG, to destroy VM channels, angiogenesis, EMT and inhibit invasion and migration.

Methods And Results: The targeting liposomes could be enriched in tumor sites through passive targeting, and the positively charged CPP was exposed and enhanced active targeting via electrostatic adsorption after being hydrolyzed by MMP2 enzymes overexpressed in the tumor microenvironment. We found that CPP modified vinorelbine and dioscin liposomes with the ideal physicochemical properties and exhibited enhanced cellular uptake. In vitro and in vivo results showed that CPP modified vinorelbine and dioscin liposomes could inhibit migration and invasion of A549 cells, destroy VM channels formation and angiogenesis, and block the EMT process. Pharmacodynamic studies showed that the targeting liposomes had obvious accumulations in tumor sites and magnificent antitumor efficiency.

Conclusion: CPP modified vinorelbine plus dioscin liposomes could provide a new strategy for NSCLC.

Citing Articles

Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment.

Kozak A, Lavrih E, Mikhaylov G, Turk B, Vasiljeva O Pharmaceutics. 2025; 17(2).

PMID: 40006643 PMC: 11859495. DOI: 10.3390/pharmaceutics17020276.

The anti-cancer activity of Dioscin: an update and future perspective.

Wang M, Zhang Y, Ni S, Sun M, Wu Q, Wu X Med Oncol. 2025; 42(3):63.

PMID: 39899128 PMC: 11790812. DOI: 10.1007/s12032-024-02572-6.

Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms.

Zamanian M, Zafari H, Osminina M, Skakodub A, Aboqader Al-Aouadi R, Golmohammadi M Animal Model Exp Med. 2024; 8(1):5-19.

PMID: 39627850 PMC: 11798740. DOI: 10.1002/ame2.12518.

Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes.

Shu H, Lv W, Ren Z, Li H, Dong T, Zhang Y Curr Drug Deliv. 2023; 21(8):1114-1127.

PMID: 37491853 DOI: 10.2174/1567201820666230724151545.

Liposomes for Tumor Targeted Therapy: A Review.

Wang S, Chen Y, Guo J, Huang Q Int J Mol Sci. 2023; 24(3).

PMID: 36768966 PMC: 9916501. DOI: 10.3390/ijms24032643.

References

Gupta B, Ramasamy T, Poudel B, Pathak S, Regmi S, Choi J . Development of Bioactive PEGylated Nanostructured Platforms for Sequential Delivery of Doxorubicin and Imatinib to Overcome Drug Resistance in Metastatic Tumors. ACS Appl Mater Interfaces. 2017; 9(11):9280-9290. DOI: 10.1021/acsami.6b09163. View

Liu J, Zhang B, Luo Z, Ding X, Li J, Dai L . Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015; 7(8):3614-26. DOI: 10.1039/c5nr00072f. View

Stenzel M, Tura A, Nassar K, Rohrbach J, Grisanti S, Luke M . Analysis of caveolin-1 and phosphoinositol-3 kinase expression in primary uveal melanomas. Clin Exp Ophthalmol. 2015; 44(5):400-9. DOI: 10.1111/ceo.12686. View

Ramasamy T, Ruttala H, Kaliraj K, Poudel K, Jin S, Choi H . Polypeptide Derivative of Metformin with the Combined Advantage of a Gene Carrier and Anticancer Activity. ACS Biomater Sci Eng. 2021; 5(10):5159-5168. DOI: 10.1021/acsbiomaterials.9b00982. View

Li F, Mei H, Gao Y, Xie X, Nie H, Li T . Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017; 145:56-71. DOI: 10.1016/j.biomaterials.2017.08.030. View

Lin C, Zhang X, Chen H, Bian Z, Zhang G, Riaz M . Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv. 2018; 25(1):256-266. PMC: 6058720. DOI: 10.1080/10717544.2018.1425777. View

Lammers P, Horn L . Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013; 11(10):1235-47. PMC: 6628716. DOI: 10.6004/jnccn.2013.0146. View

Mao G, Liu Y, Fang X, Liu Y, Fang L, Lin L . Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. Angiogenesis. 2015; 18(3):373-82. DOI: 10.1007/s10456-015-9474-5. View

Zhuge Y, Regueiro M, Tian R, Li Y, Xia X, Vazquez-Padron R . The effect of estrogen on diabetic wound healing is mediated through increasing the function of various bone marrow-derived progenitor cells. J Vasc Surg. 2018; 68(6S):127S-135S. DOI: 10.1016/j.jvs.2018.04.069. View

10.

Zhu L, Kate P, Torchilin V . Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012; 6(4):3491-8. PMC: 3337349. DOI: 10.1021/nn300524f. View

11.

Chen B, Dai W, He B, Zhang H, Wang X, Wang Y . Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 2017; 7(3):538-558. PMC: 5327631. DOI: 10.7150/thno.16684. View

12.

Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X . An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Appl Mater Interfaces. 2016; 8(5):3438-45. DOI: 10.1021/acsami.5b11619. View

13.

Wang Y, Fu M, Liu J, Yang Y, Yu Y, Li J . Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2019; 14:4071-4090. PMC: 6551515. DOI: 10.2147/IJN.S194304. View

14.

Cirligeriu L, Cimpean A, Calniceanu H, Vladau M, Sarb S, Raica M . Hyaluronic Acid/Bone Substitute Complex Implanted on Chick Embryo Chorioallantoic Membrane Induces Osteoblastic Differentiation and Angiogenesis, but not Inflammation. Int J Mol Sci. 2018; 19(12). PMC: 6320888. DOI: 10.3390/ijms19124119. View

15.

Li T, Takeoka S . A novel application of maleimide for advanced drug delivery: in vitro and in vivo evaluation of maleimide-modified pH-sensitive liposomes. Int J Nanomedicine. 2013; 8:3855-66. PMC: 3797616. DOI: 10.2147/IJN.S47749. View

16.

Ju R, Li X, Shi J, Li X, Sun M, Zeng F . Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014; 35(26):7610-21. DOI: 10.1016/j.biomaterials.2014.05.040. View

17.

Ramasamy T, Ruttala H, Gupta B, Poudel B, Choi H, Yong C . Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review. J Control Release. 2017; 258:226-253. DOI: 10.1016/j.jconrel.2017.04.043. View

18.

Ji T, Lang J, Wang J, Cai R, Zhang Y, Qi F . Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy. ACS Nano. 2017; 11(9):8668-8678. DOI: 10.1021/acsnano.7b01026. View

19.

Shafique M, Tanvetyanon T . Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther. 2019; 19(3):225-232. DOI: 10.1080/14712598.2019.1571036. View

20.

Kong L, Cai F, Yao X, Jing M, Fu M, Liu J . RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply. Cancer Sci. 2019; 111(2):621-636. PMC: 7004549. DOI: 10.1111/cas.14256. View